Role of Sphingolipid Mediator Ceramide in Obesity and Renal Injury in Mice Fed a High-Fat Diet

Krishna M. Boini, Chun Zhang, Min Xia, Justin L. Poklis, and Pin-Lan Li

Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia

Received March 31, 2010; accepted June 10, 2010

ABSTRACT

The present study tested a hypothesis that excess accumulation of sphingolipid, ceramide, its metabolites, or a combination contributes to the development of obesity and associated kidney damage. Liquid chromatography/mass spectrometry analysis demonstrated that C57BL/6J mice on the high-fat diet (HFD) had significantly increased plasma total ceramide levels compared with animals fed a low-fat diet (LFD). Treatment of mice with the acid sphingomyelinase (ASMase) inhibitor amitriptyline significantly attenuated the HFD-induced plasma ceramide levels. Corresponding to increase in plasma ceramide, the HFD significantly increased the body weight gain, plasma leptin concentration, urinary total protein and albumin excretion, glomerular damage index, and adipose tissue ASMase activity compared with the LFD-fed mice. These HFD-induced changes were also significantly attenuated by treatment of mice with amitriptyline. In addition, the decline of plasma glucose concentration after an intraperitoneal injection of insulin (0.15 U/kg b.wt.) was more sustained in mice on the HFD with amitriptyline than on the HFD alone. Intraperitoneal injection of glucose (3 g/kg b.wt.) resulted in a slow increase followed by a rapid decrease in the plasma glucose concentration in LFD and HFD plus amitriptyline-treated mice, but such blood glucose response was not observed in HFD-fed mice. Immunofluorescence analysis demonstrated a decrease in the podocin and an increase in the desmin in the glomeruli of HFD-fed mice compared with the LFD and HFD plus amitriptyline-treated mice. In conclusion, our results reveal a pivotal role for ceramide biosynthesis in obesity, metabolic syndrome, and associated kidney damage.

Introduction

Obesity has become a major global health concern, and its incidence has increased sharply in recent years. Obesity is one of the important criteria of the metabolic syndrome that is characterized by the concurrent existence of obesity, dyslipidemia, hyperglycemia, hyperinsulinemia, and hypertension. It has been shown that obesity or metabolic syndrome is a strong and independent risk factor for cardiovascular disease that causes mortality (Isomaa et al., 2001; Lakka et al., 2002) and for the development of microalbuminuria and end-stage renal disease (Chen et al., 2004).

Recent evidence suggests that adipose tissue inflammation and abnormalities in sphingolipid metabolism may contribute to the metabolic and cardiovascular risk associated with obesity (Shah et al., 2008). Sphingolipids, such as ceramide, sphingosine, and sphingosine 1-phosphate, have been implicated in the pathogenesis of obesity, insulin resistance (Summers, 2006; Holland et al., 2007), and cardiovascular disease (Augé et al., 2000, 2004; Hojjati et al., 2005). Ceramide production is mediated by the hydrolysis of membrane sphingomyelin by acid sphingomyelinase (ASMase) or neutral sphingomyelinase or by de novo synthesis via serine palmitoyltransferase and ceramide synthase (Futerman and Hannun, 2004). Ceramide is subsequently metabolized into sphingosine by ceramidases, and sphingosine can be further converted to sphingosine 1-phosphate via sphingosine kinase (Futerman and Hannun, 2004) in response to a variety of mediators, including proinflammatory cytokines, oxidative stress, and increased levels of free fatty acids. Ceramide and sphingosine inhibit insulin action and signaling in cultured cells (Summers, 2006). Inhibiting de novo ceramide synthesis prevented palmitate-mediated ceramide accumulation and inhibition of insulin signaling (Chavez et al., 2003; Powell et al., 2004; Summers, 2006). Moreover, Holland et al. (2007) demonstrated that inhibition of ceramide synthesis by using the specific serine palmitoyltransferase inhibitor myri-
ocin ameliorated obesity-induced insulin resistance. ASMase might play a role in obesity because it is overexpressed in adipose tissue of ob/ob mice (Samad et al., 2006) and appears to be involved in the pathogenesis of atherosclerosis (Marathe et al., 1999), a disease that, similarly to diabetes, is linked to obesity. It is more interesting that a recent study has reported that high-fat diet (HFD) increased the ceramide levels and ASMase expression in the adipose tissues and plasma from C57BL/6J mice (Shah et al., 2008). However, it remains unknown whether increased ASMase activity is involved in the development of obesity and associated glomerular injury or sclerosis.

The present study hypothesized that inhibition of ASMase may protect HFD-induced obesity and associated glomerular injury and also improves the metabolic status in mice. To test this hypothesis, we performed a series of analyses in mice on HFD or low-fat diet (LFD) to determine whether inhibition of ASMase activity alters ceramide production, body weight gain, and glomerular injury. Our results demonstrate that plasma ceramide may be a lipid mediator that contributes to the development of obesity and associated organ damage such as glomerular sclerosis. ASMase could be therapeutic target to reduce such lipid mediator in the plasma and improve obesity-associated metabolic syndrome and end-stage organ damage.

Materials and Methods

**Animals.** Six-week-old male C57BL/6J mice were used in the present study (The Jackson Laboratory, Bar Harbor, ME). Mice were fed either a LFD (D 12450B, 10 kcal % fat; Research Diets, New Brunswick, NJ) or a HFD (D 12492, 60 kcal % fat; Research Diets) with or without amitriptyline (Ami; Sigma-Aldrich, St. Louis, MO) in the drinking water (AMI, 1 mM in drinking water (Brand et al., 2008) for 13 weeks. All protocols were approved by the Institutional Animal Care and Use Committee of the Virginia Commonwealth University.

**Glucose Tolerance and Insulin Tolerance Test.** For determination of glucose tolerance, mice were fasted overnight, and glucose (3 g/kg b.wt.) was injected intraperitoneally. Then, a drop of blood was drawn from the tail onto a test strip of a glucometer (Central University. 840 Boini et al.

**Histological Analysis of Adipose Tissue.** Adipose tissues were removed from the mice after 12 weeks on HFD or LFD with or without amitriptyline treatment. Formalin-fixed, paraffin-embedded sections (6 μm) were cut and stained with hematoxylin and eosin.

**Monitoring of Arterial Blood Pressure in Conscious Mice.** Mean arterial pressure was measured 12 weeks after mice were treated with the LFD or HFD as described previously (Li et al., 2008). In brief, mice were anesthetized by inhalation of isoflurane, and then a catheter connected to a telemetry transmitter was implanted into the carotid artery and the transmitter was placed subcutaneously. The arterial blood pressure signal from the transmitter was received by a remote receiver and then recorded by a computer program (Data Sciences International, St. Paul, MN). Arterial blood pressure was continuously measured for 1 week after an equilibration period.

**Unrinary Total Protein and Albumin Excretion Measurement.** The 24-h urine samples were collected using metabolic cages and subjected to total protein and albumin excretion measurements. Total protein content in the urine was detected by Bradford method (Bradford, 1976) using a UV spectrophotometer. Urine albumin was detected by using a commercially available mouse albumin enzyme-linked immunosorbent assay kit (Bethyl Laboratories, Montgomery, TX).**

**Plasma Leptin Measurement.** Plasma concentrations of leptin were determined with an enzyme-linked immunosorbent kit (Linco, St. Charles, MO).

**Real-Time Reverse Transcription Polymerase Chain Reaction.** Total RNA from isolated mouse adipose tissue was extracted by using TRizol reagent (Invitrogen, Carlsbad, CA) according to the protocol of the manufacturer. RNA samples were quantified by measurement of optic absorbance at 260 and 280 nm in a spectrophotometer. The concentrations of RNA were calculated according to A260. Aliquots of total RNA (1 μg) from each sample were reverse-transcribed into cDNA according to the instructions of the first-strand cDNA synthesis kit manufacturer (Bio-Rad Laboratories, Hercules, CA). Equal amounts of the reverse transcriptional products were subjected to polymerase chain reaction amplification using SYBR Green as the metabolite of sphingomyelin, [14C]choline phosphate, was quantified. An aliquot of homogenates (20 μg) was mixed with 0.02 μCi of N-methyl-[14C]sphingomyelin in 100 μl of acidic reaction buffer containing 100 mM sodium acetate and 0.1% Triton X-100, pH 5.0, and incubated at 37°C for 15 min. The reaction was terminated by adding 1.5 ml of chloroform/methanol (2:1) and 0.2 ml of double-distilled water. The samples were then vortexed and centrifuged at 1000g for 5 min to separate into two phases. A portion of the upper aqueous phase containing [14C]choline phosphate was transferred to scintillation vials and counted in a liquid scintillation counter (Beckman Coulter, Fullerton, CA). The choline phosphate formation rate (nanomoles per minute per milligram of protein) was calculated to represent the enzyme activity.

**Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry for Quantitation of Ceramide.** Separation, identification, and quantitation of ceramide in plasma were performed by liquid chromatography/mass spectrometry. The high-performance liquid chromatography equipped with a binary pump, a vacuum degasser, a thermostated column compartment, and an autosampler (Waters, Milford, MA). The high-performance liquid chromatography separations were performed at 70°C on a reversed-phase C18 Nucleosil AB column (5 μm, 70 × 2 mm i.d.) from Macherey Nagel (Düren, Germany). The mobile phase was a gradient mixture formed as described previously (Fillet et al., 2002). The plasma lipids were extracted according to previous studies (Yi et al., 2004). To avoid any loss of lipids, the whole procedure was performed in siliconized glassware. Mass spectrometric detection was carried out with a Quattro II quadrupole mass spectrometer (Micromass, Altrincham, UK) operating under MassLynx 3.5 and configured with a Z-spray electrospray ionization source. Source conditions were described as previously (Fillet et al., 2002).
the fluorescence indicator on an iCycler system (Bio-Rad Laboratories). The primers used in this study were synthesized by Operon (Huntsville, AL), and the sequences were as follows: ASM sense, CACGTGGAT-GAGTTTGAGGT and antisense AGAGCTCCAGAGTAGTTAC; β-actin, sense TCGCTGCGCTGTCGTGTC and antisense GGCTGTCGTCACCCCATAGGA. The mRNA levels of the target gene were normalized to the β-actin mRNA levels detected from the same samples (Zhang et al., 2010a).

**Immunofluorescent Staining.** Immunofluorescent staining was performed by using frozen slides of mouse kidneys. After fixation with acetone, the slides were incubated with anti-podocin (1:100; Sigma-Aldrich) or anti-desmin (1:50; BD Biosciences, San Jose, CA) antibodies overnight at 4°C. Then, slides were washed and incubated with corresponding Texas Red-labeled secondary antibodies. Finally, the slides were washed, mounted, and subjected to fluorescent microscopy examination. The images were captured with a spot charge-coupled device camera (Diagnostic Instruments, Inc., Sterling Heights, MI). All exposure settings were kept constant for each group of kidneys.

**Results**

As illustrated in Fig. 1, HFD significantly increased the body weight of mice compared with LFD from week 3 in a time-dependent manner. Surprisingly, ASMase inhibitor amitriptyline treatment attenuated the HFD-induced increase in the body weight. However, amitriptyline alone had no effect on the body weight during the treatment period in LFD-fed mice. These data demonstrate that obesity was induced in our HFD-fed mouse model. To further test whether ASMase inhibitor amitriptyline has similar effect in obese mice, the C57BL/6J mice were fed HFD for 11 weeks. After induction of obesity, the mice were further treated with amitriptyline for 2 weeks. HFD treatment significantly increased the body weight. However, treatment of mice with amitriptyline significantly decreased the body weight in these obese mice (Supplemental Fig. 1).

Sphingolipids, such as ceramide, have been implicated in the pathogenesis of obesity. To test this possibility, we determined the effect of HFD on plasma ceramide levels in C57BL/6J WT mice. In response to the HFD, total plasma ceramide levels were significantly \((P < 0.01)\) increased in WT mice compared with LFD fed mice (Fig. 2A; Table 1), and the most abundant isoform was C24. However, additional treatment with amitriptyline, an inhibitor of ASMase, significantly decreased the HFD-induced ceramide production (Fig. 2A; Table 1). This action of amitriptyline to decrease plasma ceramide level may be translated into the magnitude of downstream effects on weight gain metabolism, gene expression, insulin signaling, glomerular injury, and leptin resis-
However, amitriptyline had no effect on proteinuria and albumin excretion with amitriptyline in HFD-fed mice significantly attenuated compared with LFD-fed mice. Treatment with amitriptyline in HFD mice.

Sensitivity of cellular glucose uptake increases upon amitriptyline treatment in HFD mice, suggesting that an insulin resistance phenomenon. As illustrated in Fig. 2B, decreased plasma ceramide level significantly attenuated HFD-induced body weight gain. At the end of the feeding regime, the mice on the HFD gained 19.1 ± 1.3 g body weight, whereas mice on the LFD gained only 7.8 ± 0.7 g. Amitriptyline treatment significantly attenuated the HFD-induced body weight gain (12.3 ± 0.4 g). Hematoxylin and eosin sections of adipose tissues showed that adipocyte size decreased in amitriptyline-treated HFD mice than in untreated HFD mice (Fig. 2C). Mean arterial pressure was similar in LFD- or HFD-fed mice with or without amitriptyline treatment (Fig. 2D). These data reveal that the HFD-induced ceramide increase has effect on the body weight, but not on the mean arterial pressure. The gain of the body weight was not due to increased food intake because the average food intake was similar in LFD- and HFD-fed mice (LFD + Ami, 134 ± 7 versus HFD + Ami, 110 ± 16 mg/g b.wt.; n = 8–10) or without amitriptyline treatment (LFD, 108 ± 5 versus HFD, 97 ± 9 mg/g b.wt.; n = 5–6). In another series of experiments, we attempted to determine the time course of ceramide in HFD-fed mice. The plasma ceramide concentration was significantly enhanced after 5 weeks of HFD treatment. In parallel to the enhancement of ceramide production at week 5, the blood glucose levels were significantly increased in WT mice fed the HFD (Supplemental Fig. 2).

Next, we tested whether inhibition of ASMase in obese mice leads to improved glucose tolerance and insulin sensitivity. Intraperitoneal injection of glucose (3 g/kg b.wt.) caused a slow increase followed by a rapid decrease in the plasma glucose concentrations in mice on the LFD and HFD with amitriptyline treatment. However, such blood glucose response was not observed in mice with the HFD alone (Fig. 3A). To test the insulin sensitivity, insulin was also injected intraperitoneally, and plasma glucose concentrations were determined. As illustrated in Fig. 3B, the decline of plasma glucose concentration after an intraperitoneal injection of insulin (0.15 U/kg b.wt.) was more sustained in mice on the HFD with amitriptyline than untreated HFD-fed mice, suggesting that an insulin sensitivity of cellular glucose uptake increases upon amitriptyline treatment in HFD mice.

Furthermore, we determined whether inhibition of ASMase contributes to the HFD-induced glomerular injury. As shown in Fig. 4, the HFD significantly increased the urinary total protein and albumin excretion compared with LFD-fed mice. Treatment with amitriptyline in HFD-fed mice significantly attenuated HFD-induced urinary total protein and albumin excretion. However, amitriptyline had no effect on proteinuria and albuminuria in LFD-fed mice. Morphological analysis showed a typical pathological change in glomerular sclerotic damage, showing expanded glomerular mesangium with hypercellularity, capillary collapse, and fibrous deposition in HFD-fed mice. The average glomerular damage index was significantly higher in HFD-fed mice compared with LFD-fed mice. Treatment with amitriptyline attenuated these HFD-induced glomerular injuries (Fig. 4). Immunofluorescent analysis showed that desmin staining was more pronounced in glomeruli of HFD-fed mice than in LFD-fed mice. Desmin is an intermediate filament protein and has been suggested as an injured podocyte marker, the expression of which is often up-regulated in various glomerular diseases, in which podocyte damage is involved (Zhang et al., 2010b). Amitriptyline treatment decreased the HFD-induced elevation of desmin staining (Fig. 5A). However, another podocyte marker, podocin, was markedly reduced in HFD-fed glomeruli compared with those in LFD-fed mice. Amitriptyline treatment almost completely attenuated the decrease in podocin staining (Fig. 5B).

To further explore the mechanism by which metabolic syndrome occurs in obese animals, we examined whether leptin resistance happens in HFD-fed mice and whether the inhibition of ASMase changes leptin resistance in these animals. Leptin is released from adipocytes, and plasma leptin concentration...
concentrations increase with adipocyte mass. Indeed, we found that plasma leptin concentrations were significantly higher in mice fed with the HFD than LFD. When mice were receiving amitriptyline, increases in plasma leptin concentrations in HFD-fed mice were significantly attenuated (Fig. 6).

Finally, we examined how HFD increased the plasma ceramide levels in mice. As shown in Fig. 7A, ASM mRNA expression in adipose tissue was significantly higher in HFD-fed mice with or without amitriptyline treatment compared with LFD-fed mice. Moreover, biochemical analysis showed that the HFD significantly increased ASMase activity in adipose tissue. In treatment with amitriptyline such HFD-induced increases in the ASMase activity in adipose tissues were substantially suppressed (Fig. 7B).

Discussion

The present study reveals that plasma ceramide plays a mechanistic role in HFD-induced obesity, insulin resistance, and associated renal injury. We demonstrated for the first time that HFD-induced increase in plasma ceramide level was attenuated with amitriptyline treatment, providing evidence for the contribution of ASMase in the advancement of obesity. Furthermore, our results suggest that a decrease in ceramide synthesis in adipose tissue may be a possible mechanism contributing to the enhanced insulin sensitivity, decreased leptin resistance, and improved glomerular injury. It appears that ceramide is an adipocyte-derived active lipid, which may serve as a sphingolipid mediator contributing to the development of obesity and corresponding organ damage such as glomerular injury.

By liquid chromatography-electrospray ionization-mass spectrometry analysis, plasma ceramide level was found significantly increased in HFD-fed mice, which was blocked when these animals were administrated the ASMase inhibitor amitriptyline. Profiling analysis of ceramide in plasma demonstrated that although C24 ceramide constituted the major ceramide component that practically determines total ceramide levels, the most dramatic changes in response to HFD were observed from less dominant ceramide isoforms in blood of mice. For example, C16 increased by 400%, C18 by 301%, and C20 or C22 by 320%. Such diversity in changes in individual ceramide species has been observed previously in various physiological and pathological conditions (Dobrzyn and Gorski, 2002; Koybasi et al., 2004). It has been suggested that changes in specific ceramide species rather than changes in total ceramide concentrations may be more important to specific pathological events, a concept now widely accepted (Shah et al., 2008). It was also found that increases in both total ceramide and specific ceramide species observed in the plasma of mice on the HFD were reduced with amitriptyline treatment, indicating that increased ceramide is derived from ASMase. In light of these data, it is tempting to speculate that improvements in the metabolic profile such as reduced weight, improved insulin resistance, improved glomerular injury, leptin resistance, and so on by amitriptyline treatment in HFD-fed mice is mediated, at least in part, by the reduction of ceramide production through ASMase. Indeed, we found that the ASMase activity and ASMase mRNA expression in adipose tissues were significantly increased in HFD-fed mice. Treatment with amitriptyline significantly attenuated such HFD-induced ASMase activity in adipose tissues. These results further confirm that HFD-induced increases in plasma ceramide level are caused mainly by activation of ASMase.

It is interesting that the reduced plasma ceramide levels upon amitriptyline treatment was accompanied with decreased body weight in HFD-fed mice, which demonstrate that the reduction of body weight in amitriptyline-treated obese mice is indeed caused by the decrease in endogenous production of ceramide. Therefore, increases in endoge-
nous production of ceramide contribute to the development of obesity, which is not associated with changes in food intake but rather with an alternate mechanism such as an increase in metabolism. Furthermore, we studied the effect of amitriptyline treatment in mice that have already developed obesity. The C57BL/6J mice were fed the HFD for 11 weeks for the induction of obesity. Administration of amitriptyline for 2 weeks in these mice significantly decreased body weight. This further supports our hypothesis that inhibition of ASMase protects HFD-induced obesity.

Although there is evidence that long-term HFD increased blood pressure in rats (Dobrian et al., 2001; Wang et al., 2003; Deutsch et al., 2009), our present study showed that mean arterial pressure was not different in mice fed HFD or treated with amitriptyline. However, the HFD for 12 weeks significantly increased urinary total protein and albumin excretion, a marker of renal injury, and inhibition of ceramide production with amitriptyline prevented such renal injury. This renal injury is independent of the elevation of arterial blood pressure because HFD has no effect on arterial blood pressure. Taken together, these findings suggest that HFD induces obesity and related glomerular injury in the kidney caused by enhanced ceramide production associated with ASMase activity.

As reported previously (Huang et al., 2006), the HFD induces insulin resistance. Treatment with amitriptyline in HFD-fed mice improved glucose tolerance and enhanced the hypoglycemic activity, suggesting an insulin sensitivity of cellular glucose uptake. The improvements in weight gain and insulin resistance upon treatment with amitriptyline in mice on the HFD were correlated strongly with decreased levels of plasma ceramide. This suggests that ceramide also contributes to the development of insulin resistance. In this regard, increasing evidence has now established a role for...
ceramide as an intermediate mechanism that links excess nutrients (e.g., saturated fatty acids) and inflammatory cytokines (e.g., tumor necrosis factor-α) to the induction of insulin resistance. For example, in vivo inhibition of de novo ceramide synthesis in various rodent models of obesity (Holland et al., 2007) improved insulin resistance. Thus, the reduction of plasma ceramide observed upon treatment with amitriptyline is a critical mechanism protecting from the HFD-induced insulin resistance and subsequent onset of diabetes in mice. In addition, we determined the changes in plasma leptin levels in mice receiving HFD with and without treatment of amitriptyline. The rationale for these measurements is that a clear link between obesity and insulin resistance, inflammation, and plasma leptin has been reported previously (Doebrian et al., 2001; Koh et al., 2005; Neels and Olefsky, 2006; Imig, 2008; Knight et al., 2008). A major hallmark of leptin resistance is hyperleptinemia, increased food intake, and decreased metabolism (Friedman and Halaas, 1998; Friedman, 1998). The present study found that the plasma leptin levels were elevated in mice fed a HFD compared with mice fed a LFD. Treatment of these HFD-fed mice with amitriptyline abolished the increase in plasma leptin level. This indicates that ASMase activation in HFD-fed mice may also be attributed to increased leptin production, which reflects obesity and metabolic status in these mice.

In previous studies, ceramide has been implicated in the regulation of kidney function. Previous reports from our laboratory (Yi et al., 2004) demonstrated that ceramide contributes to the development of chronic glomerular injury associated with hyperhomocysteinemia. Inhibitors of de novo synthesis of ceramide prevented l-homocysteine-induced ceramide formation in mesangial cells and also in the kidney and attenuated glomerular injury and proteinuria (Yi et al., 2004). In this study, we demonstrate that decreased ceramide via ASMase may have a protective role in the glomerular injury associated with obesity. In agreement with a deterioration of proteinuria, histological examinations in this study also showed that the glomerular mesangium was expanded with glomerular hypercellularity, capillary collapse, and fibroblastic deposits in HFD-fed mice, which was attenuated significantly by amitriptyline treatment, providing further evidence that glomerular injury induced by the HFD may be blocked by ASMase inhibition; therefore, this sphingomyelinase could be a target of therapeutic strategy for obesity and related end-stage organ damage.

To explore the mechanism of glomerular injury during HFD, we observed changes in podocyte function in mice exposed to the HFD with and without treatment of amitriptyline. It has been well documented that podocyte loss and dysfunction occurs with the onset and magnitude of glomerulosclerosis. Because podocytes serve as the final barrier against urinary protein loss in the normal glomeruli, any change in podocyte structure and function may be intimately associated with proteinuria and consequent glomerular sclerosis (Li et al., 2008). The present study showed that podocin protein markedly decreased in HFD-fed mice and amitriptyline treatment restored podocin expression to the level comparable with the LFD-fed mice. In addition, we found that desmin as an intermediate filament protein and a specific and sensitive podocyte injury marker increased in the glomeruli when mice received the HFD. This increased desmin expression in the glomeruli was attenuated in HFD-fed mice receiving amitriptyline. These results support the view that HFD-induced obesity-associated with increased ceramide production may result in glomerular injury. Given that amitriptyline treatment prevented both obesity and glomerular podocyte injury and consequent glomerular injury or sclerosis, it is possible that this protective action of ASMase inhibition may be due to deterioration of obesity and consequent protection of the kidney from sclerotic injury. However, our recent studies reported that ceramide serves as an intermediate pathogenic factor that directly mediates Hcys-induced podocyte injury and glomerular sclerosis through enhancement of local oxidative stress (Yi et al., 2004; Zhang et al., 2010a). It is possible that the role of ceramide in obesity-induced glomerular injury may be different from that in hyperhomocysteinemia because a circulatory ceramide is increased in obesity. However, the direct effect of ceramide as an intracellular signaling molecule, implicating in glomerular podocyte injury and glomerular sclerosis may not be excluded.

In summary, the present study demonstrated that the ASMase inhibitor amitriptyline attenuated HFD-induced obesity and obesity-associated renal injury. Our results suggest that increased ceramide production via ASMase during the HFD is one of the important pathogenic factors in the development of obesity and associated end-stage organ damage such as glomerular sclerosis. Targeting ASMase by inhibition of its activity may be a novel therapeutic strategy for treatment and prevention of obesity and associated metabolic disturbance and/or end-stage organ damage.

**References**


Address correspondence to: Dr. Pin-Lan Li, Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, 410 N, 12th St., Richmond, VA 23298. E-mail: pli@vcu.edu